PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) today issued an update regarding the second phase of its three phase, scorpion venom-derived peptide research and development program. The program consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom. The goal of the program is to empower PreveCeutical to produce Nature Identical™ peptide therapeutics to treat, regulate and prevent cancer progression. The company’s initial focus will target glioblastoma, a highly-aggressive form of brain cancer. PreveCeutical has started phase 2 of the program, comprised of re-designing the peptides to enhance their biostability while upholding their potency during screening against well-characterized and defined targets associated with brain cancer. The company’s research team employs advanced computer technology for its in-silico modelling and docking studies against identified brain cancer targets to determine critical structural features and amino acid sequences. Using its proprietary peptide linker technology, PreveCeutical will begin to re-engineer the identified peptides after they are generated from the modelling and docking studies to conserve the structural features responsible for binding and other critical activities. Each novel, uniquely designed Nature Identical™ peptide candidate will then be purified, fully characterized and added to a wide-ranging library of candidates. Upon completion of this phase, PreveCeutical will enter phase 3 and begin screening the peptides in cell-based glioblastoma models.
To view the full press release, visit http://nnw.fm/2PkyT
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com